- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Senators Enquire on Policy for Biosimilars
Within a week of Sandoz applying for approval of it's biosimlar to Amgen's Neupogen, U.S. senators want the FDA to lay down guidelines on naming these drugs.
One week after the FDA received its first request to approve a biosimilar medicine, a handful of U.S. senators has asked the U.S. Department of Health and Human services when a formal policy will be adopted for naming these medications.
Their missive was sent just as the World Health Organization suggested a new proposal for naming biosimilars, which are designed to emulate brand-name biologics and are forecast to save billions of dollars in health care costs.
At issue is whether biosimilars should be given the same International Proprietary Name, or INN, as brand-name biologics. The WHO oversees the global INN system, but individual regulatory agencies in each country are not bound by the latest WHO proposal.
As we have noted previously, the naming debate is particularly contentious and has divided the pharmaceutical industry, which has been lobbying the FDA to chart a course. A central focus of the debate is whether different INNs would hamper substitution needed for lowering health care costs.
Original report: http://on.wsj.com/1tSZlAX
Source: The Wall Street Journal
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Breast Cancer Outcomes Improved in States With Medicaid Expansion
October 24th 2024Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.
Read More
Bridging the Vaccination Gap: Insights on Global Immunization Challenges
July 30th 2024On this episode of Managed Care Cast, we speak with Jeffery A. Goad, PharmD, MPH, 2024-2025 president of the National Foundation for Infectious Diseases, on the recent report from the World Health Organization and UNICEF on public immunization rates, with national and global health implications.
Listen
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
